MAPT and Alzheimer disease: It should be noted that scopolamine is a muscarinic receptor blocker inducing many of cellular and molecular changes in Alzheimer’s disease including cholinergic dysfunction, Aβ and tau pathology, oxidative stress, mitochondrial dysfunction, neuroinflammation and apoptosis46.